


JFW

Attorney Docket No.: 5367.230-US

PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Knudsen et al

10/730,215

Application No.: To be assigned

Group Art Unit: To be assigned

Filed: October 21, 2003

Examiner: To be assigned

For: GLP-2 Derivatives

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Supplemental Information Disclosure Statement shall not be construed as a representation that no material references other than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is also enclosed.

The references are as follows:

1. U.S. Patent no. 5,834,428
2. U.S. Patent no. 5,912,229
3. U.S. Patent no. 5,952,301
4. U.S. Patent no. 5,990,077
5. U.S. Patent no. 5,994,500
6. U.S. Patent no. 6,051,557


7. U.S. Patent no. 6,184,201 B1
8. U.S. Patent no. 6,297,214 B1
9. U.S. Patent no. 6,489,295 B1
10. U.S. Patent no. 6,586,399 B1
11. U.S. Patent Application Publication no. US 2001/0021767 A1
12. U.S. Patent Application Publication no. US 2001/0027180 A1
13. U.S. Patent Application Publication no. US 2003/0040478 A1
14. U.S. Patent Application Publication no. US 2003/0109449 A1
15. U.S. Patent Application Publication no. US 2003/0158101 A1
16. U.S. Patent Application Publication no. US 2003/0162703 A1
17. WO 98/25644 A1
18. WO 98/52600 A1
19. WO 99/43361 A1
20. WO 99/58144 A1
21. WO 01/41779 A2
22. WO 01/49314 A2 and A3
23. EP 0891378 B1
24. Copy of U.S. Application S/N 10/685,368
25. Shennan et al., *Molecular and Cellular Endocrinology*; Vol. 67; 1989; pp. 93-9
26. Watanabe et al., *Biochemical and Biophysical Research Communications*; Vol. 152, No. 3; May 16, 1988; pp. 1038-1044
27. Lund et al., *Digestion*; Nov.-Dec. 1993; pp. 371-373
28. Orskov et al., *Diabetologia*; Vol. 30; 1987; pp. 874-881
29. Orskov et al., *FEBS Letters*; Vol. 247 No. 2; Apr. 1989; pp. 193-196
30. George et al., *FEBS Letters*; Vol. 192, No. 2; 1985; pp. 275-278
31. Hoosein et al., *FEBS Letters*; Vol. 178, No. 1; Dec. 1984; pp. 83-86
32. Lee et al., *The Journal of Biological Chemistry*; Vol. 267, No. 15; May 1992; pp. 10705-10708
33. Orskov et al., *Scand. J. Clin. Lab. Invest*; Vol. 47, No. 2; Apr. 1987; pp. 165-174
34. Barragan et al., *American Journal of Physiology*; Vol. 266, No. 3, Part 1; Mar. 1994; pp. E459-66
35. Brubaker et al., *Endocrinology*; Vol. 128, No. 6; 1991; pp. 3175-3182
36. Calvo et al., *J. Neurochemistry*; Vol. 64, No. 1; Jan. 1995; pp. 299-306
37. Drucker, *Pancreas*; Vol. 5, No. 4; 1990; pp. 484-488
38. Mojsov et al., *The Journal of Biological Chemistry*; Vol. 261, No. 25; Sep. 5, 1986; pp. 11880-11889
39. Orskov et al., *Endocrinology*; Vol. 119, No. 4; 1986; pp. 1467-1475
40. Madsen et al., *Endocrinology*, Vol. 133, No. 5, pages 2022-2030 (1993)
41. Siegel et al., *Reg. Peptides*, Vol. 79, pages 93-102 (1999)
42. Gallwitz et al., *Reg. Peptides*, Vol. 86, pages 103-111 (2000)
43. WO 98/03547
44. Turton et al., *Nature*, Vol. 379, pages 69-71 (1996)
45. Flint et al., *J. Clin. Invest.*, Vol. 101, No. 3, pages 515-520 (1998)
46. Gutzwiller et al., *Gut*, Vol. 44, pages 81-86 (1999)
47. Naslund et al., *Int. J. Of Obesity*, Vol. 23, pages 304-311 (1999)
48. Sorensen et al., *Int. J. Of Obesity*, Vol. 27, pages 450-456 (2003)
49. WO 02/066062 A2 & A3

50. Drucker et al., Nature Biotechnology, Vol. 15, pages 673-677 (1997)
51. US 08/422,540
52. Buhl et. al. J. of Bio. Chem., Vol. 263, No. 18, pages 8621-8624 (1988)
53. Nishi et. al., Molecular Endocrinology Vol. 4, pages 1192-1198 (1990)
54. Mentlein et al., Eur. J. Biochem., Vol 214, pages 829-835 (1993)
55. US 08/631,273
56. Peninsula Laboratories, Inc. Catalog, 1993-1994
57. Demuth et al., Chapter 1 in Dipeptidyl Peptidase IV (CD26) in Metabolism and the Immune Response, pages 1-35, (Springer, R.G. Landes Co., Austin, TX) (1995)
58. Bongers et al., Biochimica et Biophysica Acta, Vol. 1122, pages 147-153 (1992)
59. Gallwitz et al., Eur. J. Biochem., Vol. 225, pages 1151-1156 (1994)
60. Deacon et al., Diabetes, Vol. 44, pages 1126-1131 (1995)
61. Kieffer et al., Endocrinology, Vol. 136, No. 8, pages 3585-3596 (1995)
62. CA Application No. 2,137,206 to Eli Lilly
63. Tang-Christiansen, et al., Nature Medicine, Vol. 6 (7), pp. 802-7 (July 2000)
64. Substantive Arguments to Date from Opposition to European Patent 0 891 378

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the undersigned if there are any questions concerning this paper or the attached references.

The information disclosure statement submitted herewith is being filed **within** three months of the filing date of a national application or date of entry into the national stage of an international application or **before** the mailing date of a first Office action on the merits, or **before** the mailing date of a first Office action after the filing of a request for continued examination. Therefore, no fee is due. However, please charge any fees should they be required, to Novo Nordisk Pharmaceuticals, Inc. Deposit Account No. 14-1447.


Date: August 30, 2004

Respectfully submitted,

Len S. Smith, Reg. No. 43,139
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5800

Use the following customer number for all correspondence regarding this application

23650

PATENT TRADEMARK OFFICE



Attorney Docket No.: 5367.230-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Knudsen et al

Serial No.: 10/730,215

Group Art Unit: 1636

Filed: December 8, 2003

Examiner: To be assigned

For: GLP-2 Derivatives

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

I hereby certify that the attached correspondence comprising:


1. Supplemental Information Disclosure Statement
2. Form PTO-1449
3. Copy of References

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on **August 30, 2004**

Csaba Attila Szakolczai
(name of person mailing paper)


(signature of person mailing paper)

FORM PTO-1449
(Rev. 2-32)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEAtty. Docket No. **5367.230-US**Serial No. **To be assigned**INFORMATION DISCLOSURE
STATEMENT BY APPLICANTApplicant **Knudsen et al**

(Use several sheets if necessary)

Filing Date **October 21, 2003**Group **To be assigned**

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5,834,428	11/10/98	Drucker	514	12	
	5,912,229	6/15/99	Thim et al.	514	12	
	5,952,301	9/14/99	Drucker	514	12	
	5,990,077	11/23/99	Drucker	514	2	
	5,994,500	11/30/99	Drucker et al.	530	324	

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 98/25644 A1	6/18/98	PCT				
	WO 98/52600 A1	11/26/98	PCT				
	WO 99/43361 A1	9/2/99	PCT				
	WO 99/58144 A1	11/18/99	PCT				
	WO 01/41779 A2	6/14/01	PCT				
	WO 01/49314 A2 & A3	7/12/01	PCT				
	EP 0891378 B1	1/20/99	EPO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Copy of USSN 10/685,368
	Shennan et al., Molecular and Cellular Endocrinology; Vol. 67; 1989; pp. 93-99
	Watanabe et al., Biochemical and Biophysical Research Communications; Vol. 152, No. 3; May 16, 1988; pp. 1038-1044
	Lund et al., Digestion; Nov.-Dec. 1993; pp. 371-373
	Orskov et al., Diabetologia; Vol. 30; 1987; pp. 874-881
	Orskov, FEBS Letters. 247(2), pp. 193-196, Apr. 24, 1989
	George et al., FEBS Letters; Vol. 192, No. 2; 1985; pp. 275-278
	Hoosein et al., FEBS Letters; Vol. 178, No. 1; Dec. 1984; pp. 83-86
	Lee et al., The Journal of Biological Chemistry; Vol. 267, No. 15; May 1992; pp. 10705-10708
	Orskov et al., Scand. J. Clin. Lab. Invest; Vol. 47, No. 2; Apr. 1987; pp. 165-174

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449
(Rev. 2-32)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEAtty. Docket No. **5367.230-US**Serial No. **To be assigned**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant **Knudsen et al**Filing Date **October 21, 2003**Group **To be assigned**

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
		6,051,557	4/18/00	Drucker	514	12	
		6,184,201 B1	2/6/01	Drucker et al.	514	12	
		6,297,214 B1	10/2/01	Drucker	514	12	
		6,489,295 B1	12/3/02	Drucker et al.	514	12	
		6,586,399 B1	7/1/03	Drucker	514	12	
		2001/0021767 A1	9/13/01	Drucker et al.	530	320	
		2001/0027180 A1	10/4/01	Isaacs	514	12	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
		WO 98/03547	01/29/98	PCT				
		WO 02/066062 A2&A3	08/29/02	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Barragan et al., American Journal of Physiology; Vol. 266, No. 3, Part 1; Mar. 1994; pp. E459-66
		Brubaker et al., Endocrinology; Vol. 128, No. 6; 1991; pp. 3175-3182
		Calvo et al., J. Neurochemistry; Vol. 64, No. 1; Jan. 1995; pp. 299-306
		Drucker, Pancreas; Vol. 5, No. 4; 1990; pp. 484-488
		Mojsov et al., The Journal of Biological Chemistry; Vol. 261, No. 25; Sep. 5, 1986; pp. 11880-11889
		Orskov et al., Endocrinology; Vol. 119, No. 4; 1986; pp. 1467-1475
		Madsen et al., Endocrinology, Vol. 133, No. 5, pages 2022-2030 (1993)
		Siegel et al., Reg. Peptides, Vol. 79, pages 93-102 (1999)
		Gallwitz et al., Reg. Peptides, Vol. 86, pages 103-111 (2000)
		Turton et al., Nature, Vol. 379, pages 69-71 (1996)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449
(Rev. 2-32)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

Atty. Docket No. 5367.230-US

Serial No. To be assigned

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant Knudsen et al

Filing Date October 21, 2003

Group To be assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
		2003/0109449 A1	6/12/03	Drucker et al.	514	12	
		2003/0040478 A1	2/27/03	Drucker et al.	514	12	
		2003/0158101 A1	8/21/03	Drucker	514	12	
		2003/0162703 A1	8/28/03	Drucker et al.	514	12	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Flint et al., J. Clin. Invest., Vol. 101, No. 3, pages 515-520 (1998)
		Gutzwiler et al., Gut, Vol. 44, pages 81-86 (1999)
		Naslund et al., Int. J. Of Obesity, Vol. 23, pages 304-311 (1999)
		Sorensen et al., Int. J. Of Obesity, Vol. 27, pages 450-456 (2003)
		Drucker et al., Nature Biotechnology, Vol. 15, pages 673-677 (1997)
		Copy of US 08/631,273
		Buhl et al., The Journal of Biological Chemistry; Vol. 263, No. 18; Jun. 25, 1998; pp. 8621-8624
		Nishi et al., Molecular Endocrinology; 1990; 4:1192-1198
		Mentlein et al., Eur. J. Biochem., Vol 214, pages 829-835 (1993)
		US 08/422,540

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449
(Rev. 2-32)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEAtty. Docket No. **5367.230-US**Serial No. **To be assigned**INFORMATION DISCLOSURE
STATEMENT BY APPLICANTApplicant **Knudsen et al**

(Use several sheets if necessary)

Filing Date **October 21, 2003**Group **To be assigned**

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Peninsula Laboratories, Inc. Catalog, 1993-1994
		Demuth et al., Chapter 1 in Dipeptidyl Peptidase IV (CD26) in Metabolism and the Immune Response, pages 1-35, (Springer, R.G. Landes Co., Austin, TX) (1995)
		Bongers et al., Biochimica et Biophysica Acta, Vol. 1122, pages 147-153 (1992)
		Gallwitz et al., Eur. J. Biochem., Vol. 225, pages 1151-1156 (1994)
		Deacon et al., Diabetes, Vol. 44, pages 1126-1131 (1995)
		Kieffer et al., Endocrinology, Vol. 136, No. 8, pages 3585-3596 (1995)
		CA Application No. 2,137,206 to Eli Lilly
		Tang-Christiansen, et al., Nature Medicine, Vol. 6 (7), pp. 802-7 (July 2000)
		Substantive Arguments to Date from Opposition to European Patent 0 891 378
EXAMINER		DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.